Health & TechFairfax, Virginia
A personalized mRNA melanoma treatment cut recurrence risk 42%
In a Phase 3 trial, adding investigational intismeran autogene to Keytruda cut melanoma recurrence or death by 42%. Inova Schar was a top-enrolling site. The drug is not FDA-approved.
Verified · Inova Newsroom